Deficiency of dolichol-phosphate-mannose synthase-1 causes congenital disorder of glycosylation type Ie

T Imbach, B Schenk, E Schollen… - The Journal of …, 2000 - Am Soc Clin Investig
T Imbach, B Schenk, E Schollen, P Burda, A Stutz, S Grünewald, NM Bailie, MD King…
The Journal of clinical investigation, 2000Am Soc Clin Investig
Congenital disorders of glycosylation (CDG), formerly known as carbohydrate-deficient
glycoprotein syndromes, lead to diseases with variable clinical pictures. We report the
delineation of a novel type of CDG identified in 2 children presenting with severe
developmental delay, seizures, and dysmorphic features. We detected hypoglycosylation on
serum transferrin and cerebrospinal fluid β-trace protein. Lipid-linked oligosaccharides in
the endoplasmic reticulum of patient fibroblasts showed an accumulation of the dolichyl …
Congenital disorders of glycosylation (CDG), formerly known as carbohydrate-deficient glycoprotein syndromes, lead to diseases with variable clinical pictures. We report the delineation of a novel type of CDG identified in 2 children presenting with severe developmental delay, seizures, and dysmorphic features. We detected hypoglycosylation on serum transferrin and cerebrospinal fluid β-trace protein. Lipid-linked oligosaccharides in the endoplasmic reticulum of patient fibroblasts showed an accumulation of the dolichyl pyrophosphate Man5GlcNAc2 structure, compatible with the reduced dolichol-phosphate-mannose synthase (DolP-Man synthase) activity detected in these patients. Accordingly, 2 mutant alleles of the DolP-Man synthase DPM1 gene, 1 with a 274C>G transversion, the other with a 628delC deletion, were detected in both siblings. Complementation analysis using DPM1-null murine Thy1-deficient cells confirmed the detrimental effect of both mutations on the enzymatic activity. Furthermore, mannose supplementation failed to improve the glycosylation status of DPM1-deficient fibroblast cells, thus precluding a possible therapeutic application of mannose in the patients. Because DPM1 deficiency, like other subtypes of CDG-I, impairs the assembly of N-glycans, this novel glycosylation defect was named CDG-Ie.
The Journal of Clinical Investigation